Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...

After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a ...

MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...

Hypertrophic cardiomyopathy (HCM) in cats is a heart condition that may cause heart muscles to thicken. The condition reduces the heart’s efficiency. Symptoms may show in other body parts.

The AHA is expanding its initiative to improve detection, standardize care, and enhance treatment for hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy (HCM) is the most common genetic heart (cardiac) condition. It affects more than one in 500 people in the US. Genetic counseling and genetic testing can be helpful so you ...

The human heart is a muscle, but it’s also a kind of complicated balloon—a balloon that fills and empties roughly 60 to 100 times every minute, and several billion times during the course of a ...